<DOC>
	<DOC>NCT02478892</DOC>
	<brief_summary>The study is a prospective, observational, case-control study evaluating the utility of endoscopic ultrasound for the identification of preneoplastic and neoplastic pancreatic lesions in patients at high risk for pancreatic cancer, specifically those with BRCA1/2 mutations.</brief_summary>
	<brief_title>Screening for PDAC in BRCA1/2 Patients</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Informed consent provided Age greater than or equal to 18 Patients: Able and willing to attend routine followup as advised BRCA2 Mutation Carriers Patients with a history of BRCA2 Mutation, with or without manifestation of breast or ovarian cancer, over the age of 50. Any BRCA2 patient who has a first degree or 2 second degree family members with a history or pancreatic cancer will initiate screening 10 years prior to the age of onset of the index pancreatic neoplasia. BRCA1, ATM, &amp; PALB2 Mutation Carriers Any BRCA1 patient who has a first degree or 2 second degree family members with a history or pancreatic cancer will initiate screening 10 years prior to the age of onset of the index pancreatic neoplasia. Known infection with HIV, HBC, or HCV Pregnancy Esophageal strictures prior to treatment Zenkers Diverticulum prior to treatment History of abnormal or post surgical (i.e. postRouxenY Gastric Bypass) foregut anatomy precluding endoscopic ultrasound examination of the pancreas.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>high risk</keyword>
	<keyword>specifically those with BRCA1/2 mutations</keyword>
</DOC>